Regulus Therapeutics Inc

NASDAQ RGLS

Data sourced from

and

Download Data

Regulus Therapeutics Inc Dividend Payout Ratio for the year ending December 31, 2023

Regulus Therapeutics Inc Dividend Payout Ratio is NA for the year ending December 31, 2023. The dividend payout ratio measures the percentage of a company's net income that is distributed as dividends to shareholders. It is calculated by dividing dividends paid by net income. This ratio provides insights into the portion of earnings that is returned to shareholders in the form of dividends. A higher ratio indicates a larger proportion of earnings being paid out as dividends.

NASDAQ: RGLS

Regulus Therapeutics Inc

CEO	Mr. Joseph P. Hagan M.B.A.
IPO Date	Oct. 4, 2012
Location	United States
Headquarters	4224 Campus Point Court, San Diego, CA, United States, 92121
Employees	30
Sector	Healthcare
Industry	Biotechnology

Description

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Key trends